ADVA
12.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it is playing a key role in a unique research initiative extending post-quantum security to VPN networks. Leveraging the ADVA FSP 150 with ConnectGuard™ Ethernet encryption, the Quantum-Secure VPN Modules and Operation Modes (QuaSiModO) project is testing new quantum-resistant algorithms in the packet domain. It will develop viable security solutions that can protect Layer 2 and 3 data against all forms of cyberattack, including those from quantum computers. By participating in the initiative, ADVA is extending its industry-leading work with quantum-safe cryptography in optical transport to higher network layers. Other QuaSiModO project partners are the Fraunhofer Institute of Applied and Integrated Security, the Ludwig Maximilian University of Munich and genua GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005043/en/
“As part of the QuaSiModO project, we’re continuing to drive innovation in future-proof cryptography. This initiative extends comprehensive post-quantum security to VPNs and enables businesses and government institutions to protect their data from tomorrow’s attacks,” said Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Together with our partners, we’re ensuring that network security technology doesn’t fall behind in the computing power race. Our role in the project combines our experience with transport layer post-quantum security and our proven expertise when it comes to encrypting Carrier Ethernet connectivity. We’re helping to create a solution able to protect packet services today and ready to be upgraded later to comply with emerging specifications from standards bodies such as the USA’s National Institute of Standards and Technology.”
Quantum computers of sufficient size and reliability could arrive within the next 10 to 15 years. This may mean that today’s widely applied data protection technologies will no longer be sufficient. What’s more, sensitive and valuable information may be at risk right now from harvesting attacks, with attackers storing information today to decrypt it as soon as large quantum computers are available. Funded by the German Federal Ministry of Education and Research, the QuaSiModO project is researching, testing and helping to standardize quantum-resistant algorithms in VPN implementations. It aims to extend existing IPSec and MACsec communication protocols with quantum-resistant procedures and support the development of complete solutions. The initiative is utilizing ADVA FSP 150 edge devices with ConnectGuard™ Ethernet encryption technology based on an enhanced version of MACsec. The solution provides high throughput and low-latency performance as it encrypts across multiple domains and service provider networks.
“When quantum computers emerge, they’ll be able to quickly crack complex problems that would take today’s most powerful supercomputers many years to solve. That’s why enterprises, governments and communication service providers are looking to leverage security technology built on quantum-safe algorithms,” commented Alexander von Gernler, head of research, genua GmbH. “For a decade, we’ve been focused on the threat posed by large quantum computers, and much of our work in recent years has been about developing practical quantum-resistant signatures and key establishment protocols. Now, we’re leading the QuaSiModO consortium, working with ADVA and the other partners to bring post-quantum security to network Layers 2 and 3, and deliver the robust future-proof protection that classical encryption technologies simply can’t.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005043/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
